This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Computer Programs and Systems (CPSI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analysts Estimate Fullgent Genetics (FLGT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.
Fullgent Genetics (FLGT) Stock Moves -1.28%: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $56.44 in the latest trading session, marking a -1.28% move from the prior day.
Fullgent Genetics (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $61.50 in the latest trading session, marking a +0.87% move from the prior day.
Is Fulgent Genetics (FLGT) a Suitable Value Investor Stock?
by Zacks Equity Research
Let's see if Fulgent Genetics (FLGT) stock is a good choice for value-oriented investors right now from multiple angles.
Fullgent Genetics (FLGT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fullgent Genetics (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Fullgent Genetics (FLGT) closed at $65.84, marking a -0.98% move from the previous day.
4 Best Stocks With High Net Income Ratio to Grab Today
by Nitish Marwah
OPBK, BBW, EVRI, and FLGT qualified the screen for stocks with a high net income ratio.
Fullgent Genetics (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed the most recent trading day at $71.50, moving +0.14% from the previous trading session.
Fullgent Genetics (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Fullgent Genetics (FLGT) closed at $63.87, marking a +1.96% move from the previous day.
4 Stocks With High Net Income Ratio to Scoop Up
by Nitish Marwah
FLGT, AAWW, BBW, and QDEL passed the screen for the stocks with a high net income ratio.
New Strong Buy Stocks for January 26th
by Zacks Equity Research
FLGT, LPX, STC, GFED, and FBNC have been added to the Zacks Rank #1 (Strong Buy) List on January 26th.
Fullgent Genetics (FLGT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $60.72 in the latest trading session, marking a +0.03% move from the prior day.
Fullgent Genetics (FLGT) Stock Moves -0.62%: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $81.34 in the latest trading session, marking a -0.62% move from the prior day.
Fullgent Genetics (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Fullgent Genetics (FLGT) closed at $81.25, marking a +1.4% move from the previous day.
4 Profitable Stocks to Boost Returns Using Net Income Ratio
by Nitish Marwah
FLGT, LGO, CTRN, and TGH have been selected as the top picks with a high net income ratio.
Buy These 3 Stocks With Momentum Anomaly for Higher Returns
by Sandip Chakraborty
Avis Budget Group (CAR), Signet Jewelers (SIG) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
New Strong Buy Stocks for December 28th
by Zacks Equity Research
AAWW, BERY, CAL, FLGT, and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on December 28th.
Best Momentum Stocks to Buy for December 28th
by Zacks Equity Research
MUSA, JOAN, FLGT, and AHH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 28, 2021.
Has Bio-Rad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for December 21st
by Zacks Equity Research
AMTB, BBW, FLGT, and BLDR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 21, 2021.
Fullgent Genetics (FLGT) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?